DNA Aptamer Cell-SELEX for Precise Pancreatic Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating pancreatic cancer are inadequate, with limited early detection markers and therapies, leading to poor prognosis and high mortality rates due to advanced diagnosis and metastasis.
Innovation Solution
Development of DNA aptamers selected using the Cell-SELEX method that specifically bind to pancreatic cancer cells, enhanced with modifications for stability and conjugation with anticancer agents, enabling targeted diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for pancreatic cancer, then general cancer detection approaches are available, but early detection precision is insufficient and no specific early detection markers exist
Solution Approach 1:
The patent changes the detection parameter from general cancer markers to cancer-specific surface proteins identified through proteomics analysis. This parameter change enables the development of aptamers that specifically bind to pancreatic cancer cell surface proteins, thereby improving early detection precision while addressing the difficulty of detecting early-stage pancreatic cancer.
Solution Approach 2:
The patent uses Cell-SELEX technology to generate DNA aptamers that are synthetic copies designed to bind specifically to cancer cell surface proteins. These aptamers serve as artificial detection agents that replicate the binding specificity of antibodies but can be chemically synthesized, enabling precise early detection of pancreatic cancer cells.
2Reliability
If aptamers are used for cancer targeting, then high binding affinity and stability are achieved, but in vivo stability is reduced due to nuclease degradation
Solution Approach 1:
The patent modifies the chemical parameters of the aptamer structure by introducing nuclease-resistant modifications such as phosphorothioate backbones or 2'-O-methyl ribose modifications. These parameter changes protect the aptamer from nuclease degradation while maintaining its binding affinity to cancer cell surface proteins, thereby extending its half-life in vivo.
Solution Approach 2:
The patent creates composite structures by conjugating aptamers with protective molecules such as polyethylene glycol (PEG) or cholesterol. This composite material approach provides a protective layer that shields the aptamer from nucleases while maintaining its targeting capability, thus improving both stability and duration of action in vivo.
3Loss of time
If early detection is achieved, then curative surgical resection becomes possible, but most patients are already inoperable at diagnosis due to advanced stage
Solution Approach 1:
The patent implements preliminary detection action by developing aptamer-based diagnostic tools that can identify pancreatic cancer at very early stages before the disease progresses to an inoperable state. This preliminary detection enables timely intervention and surgical resection, preventing the loss of treatment opportunity that occurs with delayed diagnosis.
Solution Approach 2:
The patent replaces conventional imaging-based detection methods with a molecular recognition system using aptamers. This substitution provides higher sensitivity and specificity for early-stage detection, enabling the identification of pancreatic cancer when it is still small and localized, thereby maintaining patient operability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers demonstrate high binding affinity and stability, enhancing targeting efficiency for pancreatic cancer cells and tissues, facilitating early detection and effective treatment.
Implementation Method 1
Aptamers refer to single-stranded DNA or RNA oligonucleotides that have unique three dimensional structures and specifically bind to target molecules in a manner similar to antibodies
Implementation Method 2
DNA aptamers selected from a cancer DNA library using Cell-SELEX to bind specifically to cancer cells
Data Source
AI summary
Provided are DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells, which are optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues as well as high serum stability.